Evofem Biosciences, Inc. (EVFM)
OTCMKTS
· Delayed Price · Currency is USD
0.0086
-0.0001 (-1.15%)
Apr 29, 2026, 3:57 PM EST
Evofem Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 20.18 | 19.36 | 18.22 | 16.84 | 8.24 | Upgrade
|
| Revenue Growth (YoY) | 4.23% | 6.29% | 8.20% | 104.23% | 1748.43% | Upgrade
|
| Cost of Revenue | 4.62 | 3.83 | 6.51 | 4.42 | 4.05 | Upgrade
|
| Gross Profit | 15.57 | 15.53 | 11.71 | 12.42 | 4.19 | Upgrade
|
| Selling, General & Admin | 17.08 | 20.74 | 26.74 | 71.72 | 138.36 | Upgrade
|
| Research & Development | -3.45 | 1.84 | 2.81 | 24.82 | 32.63 | Upgrade
|
| Amortization of Goodwill & Intangibles | 0.5 | 0.62 | - | - | - | Upgrade
|
| Operating Expenses | 14.13 | 23.21 | 29.55 | 96.55 | 170.99 | Upgrade
|
| Operating Income | 1.44 | -7.68 | -17.85 | -84.12 | -166.8 | Upgrade
|
| Interest Expense | -2.64 | -2.58 | -2.63 | -2.09 | -4.73 | Upgrade
|
| Interest & Investment Income | 0.02 | 0.02 | 0.03 | 0.09 | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.36 | 0.4 | -1.9 | 33.96 | -33.66 | Upgrade
|
| EBT Excluding Unusual Items | -1.54 | -9.84 | -22.34 | -52.17 | -205.18 | Upgrade
|
| Other Unusual Items | 1.93 | 0.98 | 75.34 | -24.49 | - | Upgrade
|
| Pretax Income | 0.39 | -8.86 | 53 | -76.65 | -205.18 | Upgrade
|
| Income Tax Expense | 0 | - | 0.02 | 0.04 | 0.02 | Upgrade
|
| Earnings From Continuing Operations | 0.39 | -8.86 | 52.98 | -76.7 | -205.19 | Upgrade
|
| Net Income | 0.39 | -8.86 | 52.98 | -76.7 | -205.19 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.12 | 0.11 | 2.98 | 1.32 | 1.05 | Upgrade
|
| Net Income to Common | 0.27 | -8.97 | 50 | -78.01 | -206.24 | Upgrade
|
| Shares Outstanding (Basic) | 124 | 80 | 5 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 6,422 | 80 | 984 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 7926.85% | -91.87% | 211082.03% | 567.40% | 94.93% | Upgrade
|
| EPS (Basic) | 0.00 | -0.11 | 10.36 | -167.42 | -2953.95 | Upgrade
|
| EPS (Diluted) | 0.00 | -0.11 | 0.05 | -167.42 | -2953.95 | Upgrade
|
| Free Cash Flow | -2 | -3.9 | -8.97 | -70.75 | -149.61 | Upgrade
|
| Free Cash Flow Per Share | - | -0.05 | -0.01 | -151.84 | -2142.80 | Upgrade
|
| Gross Margin | 77.12% | 80.20% | 64.25% | 73.78% | 50.81% | Upgrade
|
| Operating Margin | 7.13% | -39.64% | -97.96% | -499.64% | -2023.30% | Upgrade
|
| Profit Margin | 1.36% | -46.30% | 274.43% | -463.35% | -2501.69% | Upgrade
|
| Free Cash Flow Margin | -9.89% | -20.14% | -49.25% | -420.21% | -1814.73% | Upgrade
|
| EBITDA | 1.96 | -7.03 | -17.37 | -83.11 | -165.78 | Upgrade
|
| EBITDA Margin | 9.70% | -36.29% | -95.34% | - | - | Upgrade
|
| D&A For EBITDA | 0.52 | 0.65 | 0.48 | 1.02 | 1.02 | Upgrade
|
| EBIT | 1.44 | -7.68 | -17.85 | -84.12 | -166.8 | Upgrade
|
| EBIT Margin | 7.13% | -39.64% | -97.96% | - | - | Upgrade
|
| Effective Tax Rate | 0.51% | - | 0.03% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.